LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

Millions of people who bought DNA tests from genetic testing service 23andme have been urged to delete their personal data ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

The Department of Biological Sciences treats the life sciences in all their breadth and diversity, including the study of molecules, cells, whole organisms, ecosystems, plants, animals and ...

Holcim has been named by the Science Based Targets Network (SBTN) as one of the first three companies globally to adopt ...

GSK is delivering consistent financial performance ... I don't think we've given the peak penetration rate. But if you look at biological penetration, it is still disappointingly low.

By Blake Brittain (Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology ...

GlaxoSmithKline, the British pharmaceuticals ... including about their health, ethnicity, and biological relationships.